The randomized, controlled Omadacycline in Acute Skin Structure Infections Study (OASIS)-2 study comparing omadacycline and linezolid for the treatment of adults with an acute bacterial skin and skin structure infection (ABSSSI) that is known or suspected to result from a gram-positive pathogen enrolled 735 patients, with 368 and 367 patients in each group, respectively.1 Patients completed the 36-Item Short Form Health Survey, version 2 (SF-36v2), a validated questionnaire on physical and mental health.
The results of the SF-36v2 were based on the standards for the intention-to-treat population.2 Patients who received omadacycline had a 3.25-point mean improvement in overall physical health (P <.001 vs baseline) and reported significant improvements across all but 1 parameter of overall health, including physical functioning, bodily pain, role physical, vitality, role emotional, mental health, and social functioning. In contrast, although the overall physical health improved with linezolid, the improvement in vitality, role emotional, mental health, and general health was not significant. Patients who received omadacycline achieved a greater improvement from baseline than the linezolid group across all quality-of-life (QOL) domains; the difference was not statistically significant.
Omadacycline significantly improves the physical component of QOL over baseline for adults with ABSSSI resulting from a gram-positive pathogen, and demonstrates a numerically greater improvement in QOL than linezolid.
1. Tzanis E, Chitra S, Curran M, et al. Improvement in quality of life for adults with acute bacterial skin and skin structure infections following treatment with omadacycline or linezolid. Presented at IDWeek 2018; San Francisco, CA; October 3-7, 2018.
2. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:3130-3139. Erratum in: Spine (Phila Pa 1976). 2001;26:2062.